Taysha Gene Therapies Q3 EPS $(0.93) Down From $(0.64) YoY, Sales $4.75M
Portfolio Pulse from Benzinga Newsdesk
Taysha Gene Therapies (NASDAQ:TSHA) reported a larger quarterly loss of $(0.93) per share in Q3, a 45.31% increase from the $(0.64) per share loss reported in the same quarter last year. Sales for the quarter were $4.75 million.
November 14, 2023 | 9:14 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Taysha Gene Therapies reported a significant increase in its quarterly loss, with EPS down to $(0.93) from $(0.64) YoY, alongside sales of $4.75 million.
The reported increase in losses is typically seen as a negative indicator for a company's financial health and may lead to a decrease in investor confidence, potentially impacting the stock price negatively in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100